RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재

      Enterobacteriaceae에 대한 β-Lactam제 감수성시험 기준 및 Extended-Spectrum β-Lactamase와 Carbapenemase 검출을 위한 전략 = Strategies for Interpretive Standards of β-Lactams Susceptibility Testing and Identification of Extended-Spectrum β-Lactamases and Carbapenemases in Enterobacteriaceae

      한글로보기

      https://www.riss.kr/link?id=A101574761

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have recently revised the susceptibility interpretive criteria of oxyimino-β-lactams and carbapenems for Enterobacteriaceae. According to the new criteria, susceptibility testing results are sufficient to detect extended-spectrum β-lactamases (ESBLs) and carbapenemases; it is not necessary to perform ESBL or carbapenemase detection tests for therapeutic purposes. Thus, it has been recommended that these related tests be performed only for infection control. These changes in the susceptibility guidelines are supported by some clinical cases and the results of pharmacodynamic and animal studies. However, differences still exist between the breakpoints established by the CLSI and EUCAST with regard to some oxyimino-β-lactam and carbapenem antibiotics, in particular, the breakpoints for ceftazidime and cefepime established by the CLSI are higher than those established by the EUCAST. Also, similar numbers of successful and unsuccessful cases have been reported regarding the use of cephalosporins or carbapenems in treating infections caused by low-minimal inhibitory concentration (MIC) ESBL-producers or low-MIC carbapenemase-producers. Finally, routine susceptibility test methods are not as accurate as research-purpose test methods, showing differences in MICs ranging approximately from 1 to 8 μg/mL. In conclusion, it is strategically prudent to continue to perform ESBL and carbapenemase detection tests and to avoid the use of the corresponding antimicrobial agents for the treatment of ESBL- or carbapenemase-producing bacterial infections.
      번역하기

      The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have recently revised the susceptibility interpretive criteria of oxyimino-β-lactams and carbapenems for Enterobacteria...

      The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have recently revised the susceptibility interpretive criteria of oxyimino-β-lactams and carbapenems for Enterobacteriaceae. According to the new criteria, susceptibility testing results are sufficient to detect extended-spectrum β-lactamases (ESBLs) and carbapenemases; it is not necessary to perform ESBL or carbapenemase detection tests for therapeutic purposes. Thus, it has been recommended that these related tests be performed only for infection control. These changes in the susceptibility guidelines are supported by some clinical cases and the results of pharmacodynamic and animal studies. However, differences still exist between the breakpoints established by the CLSI and EUCAST with regard to some oxyimino-β-lactam and carbapenem antibiotics, in particular, the breakpoints for ceftazidime and cefepime established by the CLSI are higher than those established by the EUCAST. Also, similar numbers of successful and unsuccessful cases have been reported regarding the use of cephalosporins or carbapenems in treating infections caused by low-minimal inhibitory concentration (MIC) ESBL-producers or low-MIC carbapenemase-producers. Finally, routine susceptibility test methods are not as accurate as research-purpose test methods, showing differences in MICs ranging approximately from 1 to 8 μg/mL. In conclusion, it is strategically prudent to continue to perform ESBL and carbapenemase detection tests and to avoid the use of the corresponding antimicrobial agents for the treatment of ESBL- or carbapenemase-producing bacterial infections.

      더보기

      참고문헌 (Reference)

      1 Girlich D, "Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae" 50 : 477-479, 2012

      2 Song W, "Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC beta-lactamases and extendedspectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis" 57 : 315-318, 2007

      3 Andes D, "Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations" 11 (11): 10-17, 2005

      4 Nordmann P, "The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria" 9 : 228-236, 2009

      5 Paul M, "Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis" 54 : 4851-4863, 2010

      6 Shin SY, "Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36" 61 : 239-245, 2012

      7 Dortet L, "Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test" 56 : 6437-6440, 2012

      8 Nordmann P, "Rapid detection of carbapenemaseproducing Enterobacteriaceae" 18 : 1503-1507, 2012

      9 Daikos GL, "Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections" 53 : 1868-1873, 2009

      10 Park YJ, "Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli" 71 : 87-89, 2011

      1 Girlich D, "Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae" 50 : 477-479, 2012

      2 Song W, "Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC beta-lactamases and extendedspectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis" 57 : 315-318, 2007

      3 Andes D, "Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations" 11 (11): 10-17, 2005

      4 Nordmann P, "The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria" 9 : 228-236, 2009

      5 Paul M, "Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis" 54 : 4851-4863, 2010

      6 Shin SY, "Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36" 61 : 239-245, 2012

      7 Dortet L, "Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test" 56 : 6437-6440, 2012

      8 Nordmann P, "Rapid detection of carbapenemaseproducing Enterobacteriaceae" 18 : 1503-1507, 2012

      9 Daikos GL, "Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections" 53 : 1868-1873, 2009

      10 Park YJ, "Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli" 71 : 87-89, 2011

      11 Ito H, "Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens" 39 : 824-829, 1995

      12 Clinical and Laboratory Standards Institute, "Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement. Document M100-S21"

      13 Clinical and Laboratory Standards Institute, "Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Document M100-S19"

      14 Bin C, "Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli" 56 : 351-357, 2006

      15 Paterson DL, "Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory" 39 : 2206-2212, 2001

      16 Poirel L, "OXA-48-like carbapenemases: the phantom menace" 67 : 1597-1606, 2012

      17 Lee K, "Novel acquired metallo-beta-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea" 49 : 4485-4491, 2005

      18 Woodford N, "Multiresistant gramnegative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance" 35 : 736-755, 2011

      19 Schwaber MJ, "Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis" 60 : 913-920, 2007

      20 Kitchel B, "Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258" 53 : 3365-3370, 2009

      21 Clinical and Laboratory Standards Institute, "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard Seventh Edition. Document M7-A7"

      22 Walsh TR, "Metallo-betalactamases: the quiet before the storm?" 18 : 306-325, 2005

      23 Rhee JY, "KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea" 54 : 2278-2279, 2010

      24 노경호, "Isolation of a Klebsiella pneumoniae Isolate of Sequence Type 258 Producing KPC-2 Carbapenemase in Korea" 대한진단검사의학회 31 (31): 298-301, 2011

      25 Coudron PE, "Inhibitor-based methods for detection of plasmidmediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis" 43 : 4163-4167, 2005

      26 Song W, "In vivo selection of carbapenem-resistant Klebsiella pneumoniae by OmpK36 loss during meropenem treatment" 65 : 447-449, 2009

      27 이경원, "Further Increases in Carbapenem-, Amikacin-, and Fluoroquinolone-Resistant Isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR Study 2009" 연세대학교의과대학 52 (52): 793-802, 2011

      28 Leclercq R, "EUCAST expert rules in antimicrobial susceptibility testing" 19 : 141-160, 2013

      29 European Committee on Antimicrobial Susceptibility Testing, "EUCAST clinical breakpoint v 3.1"

      30 Cohen Stuart J, "Dutch Working Party on the Detection of Highly Resistant Microorganisms. Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteriaceae" 36 : 205-210, 2010

      31 Giakkoupi P, "Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates" 43 : 494-496, 2005

      32 Maglio D, "Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula" 48 : 1941-1947, 2004

      33 Thomson KS, "Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests" 36 : 1877-1882, 1992

      34 Song W, "Detection of extended-spectrum beta-lactamases by using boronic acid as an AmpC beta-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli" 45 : 1180-1184, 2007

      35 Katsanis GP, "Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases" 32 : 691-696, 1994

      36 Lat A, "Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest" 49 : 1795-1798, 2011

      37 송원근, "Comparison of Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Breakpoints for β-Lactams in Enterobacteriaceae Producing Extended-Spectrumβ-Lactamases and/or Plasmid-Mediated AmpCβ-Lactamases" 대한임상미생물학회 14 (14): 24-29, 2011

      38 Tsakris A, "Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of klebsiella pneumoniae carbapenemase-producing enterobacteriaceae clinical isolates" 49 : 2804-2809, 2011

      39 Weisenberg SA, "Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase- producing K. pneumoniae after treatment with imipenem or meropenem" 64 : 233-235, 2009

      40 Queenan AM, "Carbapenemases: the versatile betalactamases" 20 : 440-458, 2007

      41 Jeong SH, "Boronic acid disk tests for identification of extended-spectrum beta-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC beta-lactamases" 31 : 467-471, 2008

      42 Ho PL, "Bacteremia caused by Escherichia coli producing extended-spectrum betalactamase: a case-control study of risk factors and outcomes" 34 : 567-573, 2002

      43 Livermore DM, "Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?" 67 : 1569-1577, 2012

      44 Giske CG, "A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin" 17 : 552-556, 2011

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 재인증평가 신청대상 (재인증)
      2020-01-01 평가 등재학술지 선정 (재인증) KCI등재
      2019-12-01 평가 등재후보로 하락 (계속평가) KCI등재후보
      2016-01-01 평가 등재학술지 유지 (계속평가) KCI등재
      2013-03-11 학술지명변경 한글명 : 대한임상미생물학회지 -> Annals of Clinical Microbiology
      외국어명 : Korean Journal of Clinical Microbiology -> Annals of Clinical Microbiology
      KCI등재
      2012-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2008-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2007-01-01 평가 등재후보학술지 유지 () KCI등재후보
      2005-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.19 0.19 0.26
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.22 0.2 0.651 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼